Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25081057.
- Also identified by DOI 10.1038/ncomms5563 and PMC identifier 4143949.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tuberous sclerosis complex (TSC), caused by dominant mutations in either TSC1 or TSC2 tumour suppressor genes is characterized by the presence of brain malformations, the cortical tubers that are thought to contribute to the generation of pharmacoresistant epilepsy. Here we report that tuberless heterozygote Tsc1(+/-) mice show functional upregulation of cortical GluN2C-containing N-methyl-D-aspartate receptors (NMDARs) in an mTOR-dependent manner and exhibit recurrent, unprovoked seizures during early postnatal life (<P19). Seizures are generated intracortically in the granular layer of the neocortex. Slow kinetics of aberrant GluN2C-mediated currents in spiny stellate cells promotes excessive temporal integration of persistent NMDAR-mediated recurrent excitation and seizure generation. Accordingly, specific GluN2C/D antagonists block seizures in Tsc1(+/-) mice in vivo and in vitro. Likewise, GluN2C expression is upregulated in TSC human surgical resections, and a GluN2C/D antagonist reduces paroxysmal hyperexcitability. Thus, GluN2C receptor constitutes a promising molecular target to treat epilepsy in TSC patients.
Medical subject headings
- Anticonvulsants
- Epilepsy
- Pyrazoles
- Quinolones
- Receptors, N-Methyl-D-Aspartate
- TOR Serine-Threonine Kinases
- Tuberous Sclerosis
- Tumor Suppressor Proteins